With regard to measure reporting, we estimate a decrease in burden of 267 hours (3,200 HOPDs 50 percent of HOPDs 0.167 hours per HOPD) at a savings of $14,701 (267 hours $55.06/hour) for voluntary reporting for the CY 2025 reporting period and 533 hours annually (0.167 hours 3,200 HOPDs) at a savings of $29,347 (533 hours $55.06/hour) for mandatory reporting beginning with the CY 2026 reporting period
Comment: A commenter requested that CMS reassign CPT code 0515T to New Technology APC 1576Level 39 ($15,001-$20,000) to ensure that there is adequate payment for the non-device costs as this code is tentatively approved for pass-through payment (device costs)
Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should not be used during pregnancy due to potential fetal harm
Prawnie prawdopodobnie nikt
Shipping, Delivery, and Risk Shipping estimates are not guarantees
Use of antacids Coadministration of antacids and this medicine may reduce the absorption of this medicine
